Physician profile
Jonathan Martinez
NPI 1750491908
$5,355.36
in general payments reported to CMS, 2019-2025
35 companies · $782 in 2025
The $782 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,407 · 2022: $1,241 · 2023: $940 · 2024: $985 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.31 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,320.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Esperion Therapeutics, INC. | $647.01 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $410.32 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $385.02 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $307.00 | 2021-2023 | |
| Astellas Pharma US INC | $305.83 | 2021-2025 | Veozah, Myrbetriq |
| Horizon Therapeutics Plc | $206.26 | 2021-2022 | |
| Abbvie INC. | $200.16 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.33 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $179.42 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $110.79 | 2022-2023 | |
| Genzyme Corporation | $107.69 | 2022 | |
| Baxter Healthcare | $98.18 | 2022 | |
| Amarin Pharma, INC. | $91.56 | 2021-2023 | |
| Ardelyx, INC. | $75.51 | 2023-2024 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.83 | 2021-2024 | Xifaxan |
| Pfizer INC. | $62.00 | 2023 | |
| Arbor Pharmaceuticals, INC. | $56.56 | 2021-2022 | |
| Daiichi Sankyo INC. | $54.50 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $54.34 | 2021-2022 | |
| Shield Therapeutics INC | $46.78 | 2023-2025 | Accrufer |
| Xeris Pharmaceuticals, INC. | $44.75 | 2022-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.87 | 2022 | |
| Mannkind Corporation | $38.89 | 2022 | |
| Abbott Laboratories | $35.45 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.68 | 2025 | |
| Ironwood Pharmaceuticals, INC | $34.01 | 2024 | |
| Amgen INC. | $30.22 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $21.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.61 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $19.46 | 2025 | Zenpep |
| Biohaven Pharmaceuticals, INC. | $16.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.24 | 2025 | Uzedy |
| Exact Sciences Corporation | $14.12 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.